Compare Stocks: BPMUF, TNGX, ELVN, and TLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMUF Basilea Pharmaceutica	$77.40	$67.65	$59.29 ▼ $77.40	$1.02B	0.22	5 shs	N/A
ELVN Enliven Therapeutics	$54.32 -3.4%	$56.40	$14.78 ▼ $62.32	$3.98B	0.3	805,382 shs	995,808 shs
TLX Telix Pharmaceuticals	$11.29 -5.1%	$11.23	$6.28 ▼ $12.48	$3.84B	-0.17	184,032 shs	414,798 shs
TNGX Tango Therapeutics	$23.78 +1.8%	$26.35	$6.38 ▼ $34.39	$4.01B	1.12	2.13 million shs	2.28 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMUF Basilea Pharmaceutica	0.00%	0.00%	+18.17%	+28.41%	+14.24%
ELVN Enliven Therapeutics	0.00%	-8.43%	-6.44%	+17.75%	+182.62%
TLX Telix Pharmaceuticals	0.00%	-5.44%	-8.43%	+18.10%	+16.51%
TNGX Tango Therapeutics	0.00%	+5.60%	-7.29%	-23.14%	+273.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMUF Basilea Pharmaceutica	$77.40	$67.65	$59.29 ▼ $77.40	$1.02B	0.22	5 shs	N/A
ELVN Enliven Therapeutics	$54.32 -3.4%	$56.40	$14.78 ▼ $62.32	$3.98B	0.3	805,382 shs	995,808 shs
TLX Telix Pharmaceuticals	$11.29 -5.1%	$11.23	$6.28 ▼ $12.48	$3.84B	-0.17	184,032 shs	414,798 shs
TNGX Tango Therapeutics	$23.78 +1.8%	$26.35	$6.38 ▼ $34.39	$4.01B	1.12	2.13 million shs	2.28 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMUF Basilea Pharmaceutica	0.00%	0.00%	+18.17%	+28.41%	+14.24%
ELVN Enliven Therapeutics	0.00%	-8.43%	-6.44%	+17.75%	+182.62%
TLX Telix Pharmaceuticals	0.00%	-5.44%	-8.43%	+18.10%	+16.51%
TNGX Tango Therapeutics	0.00%	+5.60%	-7.29%	-23.14%	+273.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMUF Basilea Pharmaceutica	2.00	Hold	N/A	N/A
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	38.07% Upside
TLX Telix Pharmaceuticals	2.86	Moderate Buy	$20.40	80.69% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	82.77% Upside

Current Analyst Ratings Breakdown

Latest BPMUF, TNGX, ELVN, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	ELVN Enliven Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$80.00 ➝ $78.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMUF Basilea Pharmaceutica	$280.43M	3.63	$3.85 per share	20.11	$11.73 per share	6.60
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
TLX Telix Pharmaceuticals	$803.79M	4.77	$0.04 per share	267.77	$1.23 per share	9.18
TNGX Tango Therapeutics	$62.38M	64.28	N/A	N/A	$2.57 per share	9.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMUF Basilea Pharmaceutica	$48.57M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	188.17	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest BPMUF, TNGX, ELVN, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMUF Basilea Pharmaceutica	0.59	5.11	4.68
ELVN Enliven Therapeutics	N/A	64.07	64.07
TLX Telix Pharmaceuticals	1.16	2.01	1.85
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMUF Basilea Pharmaceutica	N/A
ELVN Enliven Therapeutics	95.08%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
BPMUF Basilea Pharmaceutica	N/A
ELVN Enliven Therapeutics	3.00%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMUF Basilea Pharmaceutica	189	13.17 million	N/A	Not Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

BPMUF, TNGX, ELVN, and TLX Headlines

Recent News About These Companies

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

September 10 at 12:31 PM | zacks.com

Tango Therapeutics, Inc. $TNGX Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 10 at 4:48 AM | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.5% - Still a Buy?

September 9, 2026 | marketbeat.com

Legal & General Group Plc Makes New $2.68 Million Investment in Tango Therapeutics, Inc. $TNGX

September 6, 2026 | marketbeat.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

390,920 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Bank of New York Mellon Corp

September 2, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 2, 2026 | americanbankingnews.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

181,212 Shares in Tango Therapeutics, Inc. $TNGX Purchased by The Manufacturers Life Insurance Company

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Increases Holdings in Tango Therapeutics, Inc. $TNGX

September 1, 2026 | marketbeat.com

Nantahala Capital Management LLC Takes Position in Tango Therapeutics, Inc. $TNGX

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Tango Therapeutics, Inc. $TNGX

August 28, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Raises Stock Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Invests $157.99 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Boone Capital Management LLC Invests $14.24 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 4.8% - Here's Why

August 26, 2026 | marketbeat.com

636,070 Shares in Tango Therapeutics, Inc. $TNGX Bought by Connor Clark & Lunn Investment Management Ltd.

August 26, 2026 | marketbeat.com

Deutsche Bank AG Acquires Shares of 144,477 Tango Therapeutics, Inc. $TNGX

August 26, 2026 | marketbeat.com

BlackRock Inc. Invests $388.83 Million in Tango Therapeutics, Inc. $TNGX

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMUF, TNGX, ELVN, and TLX Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

$77.40 0.00 (0.00%)

As of 09/11/2026

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Enliven Therapeutics NASDAQ:ELVN

$54.32 -1.91 (-3.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$54.32 +0.01 (+0.01%)

As of 09/11/2026 07:56 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Telix Pharmaceuticals NASDAQ:TLX

$11.29 -0.61 (-5.13%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.16 -0.13 (-1.14%)

As of 09/11/2026 07:53 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Tango Therapeutics NASDAQ:TNGX

$23.78 +0.41 (+1.75%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$23.78 -0.01 (-0.02%)

As of 09/11/2026 07:30 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMUF, TNGX, ELVN, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMUF, TNGX, ELVN, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMUF, TNGX, ELVN, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMUF, TNGX, ELVN, and TLX Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

Enliven Therapeutics NASDAQ:ELVN

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMUF, TNGX, ELVN, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMUF, TNGX, ELVN, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMUF, TNGX, ELVN, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMUF, TNGX, ELVN, and TLX Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

Enliven Therapeutics NASDAQ:ELVN

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools